Report cover image

Community Acquired Pneumonia Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146889

Description

Community acquired pneumonia is one of the most common infections, estimated to occur in 248 of 10,000 adults per year in the United States. The incidence varies across different regions such as 31.2 per 10,000 in the United Kingdom. Therefore, researchers are emphasizing on developing high-quality and potent drugs to manage the disease effectively.

Report Coverage

The Community Acquired Pneumonia Drug Pipeline Report by Expert Market Research gives comprehensive insights into community acquired pneumonia clinical trials. It covers various aspects related to the details of each of these drugs under development for community acquired pneumonia. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The community acquired pneumonia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from community acquired pneumonia.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing community acquired pneumonia product development activities related to community acquired pneumonia.  Moreover, community acquired pneumonia collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.

Community Acquired Pneumonia Drug Pipeline Outlook

Community acquired pneumonia is a common type of pneumonia that can be used caused by germs like bacteria, fungi or viruses. Symptoms include cough, fever, chills and shortness of breath. The treatment may differ based on the type of pneumia. Antibiotics are advised for bacterial pneumonia whereas antivirals are prescribed for viral pneumonia. In addition, oxygen therapy and other breathing treatments are also advised by healthcare practitioners.

The community acquired pneumonia treatment landscape includes macrolides such as azithromycin or doxycycline for healthy individuals. Those affected with comorbidities may require combination drug therapies like beta-lactam/macrolide combinations or respiratory fluoroquinolones.

Community Acquired Pneumonia – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of community acquired pneumonia drug candidates based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class

EMR’s community acquired pneumonia therapeutic assessment report covers 50+ drug analyses based on drug classes:
  • Beta-Lactam Antibiotics
  • Macrolides
  • Fluoroquinolones
  • Glycopeptides
  • Tetracyclines
  • Oxazolidinones
By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
  • Oral
  • Parenteral
  • Others
Community Acquired Pneumonia – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for community acquired pneumonia. There are around 77 drugs in phase III of community acquired pneumonia drugs.

Community Acquired Pneumonia – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under community acquired pneumonia pipeline analysis include beta-lactam antibiotics, macrolides, fluoroquinolones, glycopeptides, tetracyclines, and oxazolidinones. The choice of treatment depends on the site of infection, the patient's age, potential resistance patterns, and other underlying health symptoms.

Community Acquired Pneumonia Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the community acquired pneumonia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in community acquired pneumonia clinical trials:
  • Pfizer
  • Aptarion Biotech AG
  • Basilea Pharmaceutica
  • Paratek Pharmaceuticals Inc
  • Nabriva Therapeutics AG
  • Novexel Inc
  • TaiGen Biotechnology Co., Ltd.
Community Acquired Pneumonia – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for community acquired pneumonia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of community acquired pneumonia drug candidates.

AON-D21

Designed by Aptarion Biotech AG, this drug is in Phase 2 of a multi-centre, exploratory, randomised, double-blind, placebo-controlled clinical trial. The trial aims to compare its efficacy, pharmacokinetics, pharmacodynamics and safety in patients affected with severe community acquired pneumonia and have been admitted to ICU.

NXL103

Sponsored by Novexel Inc., the community acquired pneumonia drug candidate NXL103 is in Phase 2 of a double-blind, multicenter, randomized comparative study to treat the efficacy, safety and tolerability of its oral formulation for treating community acquired pneumonia in adults. This interventional study has around 302 patients.

Ceftobiprole

Ceftobiprole is in Phase 3 of a randomized, investigator-blind, active blind study and it is being investigated against cephalosporin with or without vancomycin, which is a standard of care treatment for pediatric patients.

Omadacycline

Sponsored by Paratek Pharmaceuticals Inc., the drug is under investigation to treat adults affected with community-acquired bacterial pneumonia.

Reasons To Buy This Report

The Community Acquired Pneumonia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for community acquired pneumonia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into community acquired pneumonia collaborations, regulatory environments, and potential growth opportunities within community acquired pneumonia pipeline insights.

Key Questions Answered in the Community Acquired Pneumonia – Pipeline Insight Report  
  • Which companies/institutions are leading the community acquired pneumonia drug development?
  • What is the efficacy and safety profile of community acquired pneumonia pipeline drugs?
  • Which company is leading the community acquired pneumonia pipeline development activities?
  • What is the current community acquired pneumonia commercial assessment?
  • What are the opportunities and challenges present in the community acquired pneumonia drug pipeline landscape?
  • What is the efficacy and safety profile of community acquired pneumonia pipeline drugs?
  • Which company is conducting major trials for community acquired pneumonia drugs?
  • Which companies/institutions are involved in community acquired pneumonia collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in community acquired pneumonia?
Related Reports

Global Pneumonia Treatment Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Community Acquired Pneumonia
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Community Acquired Pneumonia: Epidemiology Snapshot
5.1 Community Acquired Pneumonia Incidence by Key Markets
5.2 Community Acquired Pneumonia– Patients Seeking Treatment in Key Markets
6 Community Acquired Pneumonia: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Community Acquired Pneumonia: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Community Acquired Pneumonia, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Community Acquired Pneumonia Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Community Acquired Pneumonia Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Oral Nemonoxacin
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Ceftobiprole Medocaril
10.2.3 Other Drugs
11 Community Acquired Pneumonia Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 NXL103
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Faropenem
11.2.3 AON-D21
11.2.4 Other Drugs
12 Community Acquired Pneumonia Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Omadacycline
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Community Acquired Pneumonia Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Drug 2
13.2.3 Other Drugs
14 Community Acquired Pneumonia, Key Drug Pipeline Companies
14.1 Pfizer
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Aptarion Biotech AG
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Basilea Pharmaceutica
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Paratek Pharmaceuticals Inc
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Nabriva Therapeutics AG
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Novexel Inc
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 TaiGen Biotechnology Co., Ltd.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us